Benzinga | Dec 8, 2021 07:31AM EST

Cybin Confirms Scientific Advice Meeting With UK Medical And Healthcare Products Regulatory Agency For Q1 2022 For Lead Candidate CYB003 For The Treatment Of Major Depressive Disorder And Alcohol Use Disorder

Cybin Inc. (NEO:CYBN) (NYSE:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics(tm)" is pleased to announce that it has confirmed a scientific advice meeting with the UK Medical and Healthcare Products Regulatory Agency ("MHRA") for the first quarter of calendar year 2022. This program milestone brings the Company closer toward advancing its lead investigational candidate CYB003 into clinical development for the treatment of major depressive disorder ("MDD") and alcohol use disorder ("AUD").